Aug 18 (Reuters) - Novo Nordisk said on

Monday that it was launching a new offer for self-paying type 2

diabetes patients in the U.S. to access Ozempic for $499 per

month.

The company said this was part of its ongoing efforts to

explore new collaborations and approaches towards improving

access to authentic semaglutide medicines.

It said the offer would be available through multiple

platforms, including through telehealth service GoodRx ( GDRX ).